Why a universal antiretroviral regimen?
In 2015, with its ‘treat all’ recommendation, WHO removed all restrictions on eligibility for antiretroviral therapy (ART) among HIV-positive people. WHO estimates that by the end of 2018, 20 million people worldwide will be receiving combination ART. An additional 15–17 million will be in need of ART but unable to access or afford it . Most of the existing supply of antiretrovirals (ARVs) is provided through international agencies, such as The United States President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund, or governments of low and middle-income countries (LMICs), all of which face stable or shrinking healthcare budgets.